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Abstract—The purpose of this study was to determine if ambulatory blood pressure measurement predicted total and
cardiovascular mortality over and beyond clinic blood pressure measurement and other cardiovascular risk factors; 5292
untreated hypertensive patients referred to a single blood pressure clinic who had clinic and ambulatory blood pressure
measurement at baseline were followed up in a prospective study of mortality outcome. Multiple Cox regression was
used to model time to total and cause-specific mortality for ambulatory blood pressure measurement while adjusting for
clinic blood pressure measurement and other risk factors at baseline. There were 646 deaths (of which 389 were
cardiovascular) during a median follow-up period of 8.4 years. With adjustment for gender, age, risk indices, and clinic
blood pressure, higher mean values of ambulatory blood pressure were independent predictors for cardiovascular
mortality. The relative hazard ratio for each 10-mm Hg increase in systolic blood pressure was 1.12 (1.06 to 1.18;
P0.001) for daytime and 1.21 (1.15 to 1.27; P0.001) for nighttime systolic blood pressure. The hazard ratios for each
5-mm Hg increase in diastolic blood pressure were 1.02 (0.99 to 1.07; PNS) for daytime and 1.09 (1.04 to 1.13;
P0.01) for nighttime diastolic pressures. The hazard ratios for nighttime ambulatory blood pressure remained
significant after adjustment for daytime ambulatory blood pressure. These results have 2 important clinical messages:
ambulatory measurement of blood pressure is superior to clinic measurement in predicting cardiovascular mortality, and
nighttime blood pressure is the most potent predictor of outcome. (Hypertension. 2005;46:156-161.)
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The most commonly used technique of blood pressuremeasurement in clinical practice is the auscultatory
method with a mercury sphygmomanometer and stethoscope.
A metaanalysis of clinic blood pressure measurement
(CBPM) in 1 million adults participating in 61 prospective
studies showed that a 10-mm Hg higher usual systolic blood
pressure (SBP) or 5-mm Hg higher usual diastolic blood
pressure (DBP) would be associated with 40% higher risk
of stroke death and 30% higher risk of death from ischemic
heart disease and other vascular causes.1 There are, however,
numerous criticisms of CBPM, which include interobserver
and intraobserver variability, and terminal digit preferenc-
es,2,3 all of which may bias the accuracy of measurement.
Moreover, CBPM cannot detect white-coat hypertension, the
prevalence of which can be as high as 30%.4
There is growing evidence from a number of small studies
that ambulatory blood pressure measurement (ABPM) is a
better predictor of outcome than CBPM,5–13 but only one
large Japanese population study has shown ABPM to be
better predictor of cardiovascular mortality than CBPM.8
Similarly, evidence is accumulating to demonstrate that
nighttime pressure is superior to daytime pressure in predict-
ing cardiovascular outcome.7,14–21 The objective of this study,
therefore, was to determine the additional predictive value of
ABPM over and above CBPM, and also to estimate the
superiority of nighttime pressure over daytime pressure in a
large Western population of untreated hypertensive patients
from a single center followed-up for up to 20 years.
Methods
Study Population
The Blood Pressure Unit (formerly located at the Charitable Infir-
mary and now based at Beaumont Hospital in Dublin) has been in
operation for 22 years. The majority of patients are referred to the
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Unit by their family doctors because of an elevated CBPM; 14 414
such patients were entered into a database during the study period
(June 1, 1980 to September 30, 2002). To be eligible for inclusion in
the present report, patients had to be either untreated at baseline or to
have had all antihypertensive drugs discontinued for 1 week before
their baseline visit to the unit; demographic details and cardiovas-
cular risk factors (sex, age, body mass index, smoking status,
presence of diabetes mellitus, and history of previous cardiovascular
events) had to be recorded; and the ABPM record had to include at
least 10 daytime and 5 nighttime readings. Because of insufficient
ABPM measurements, 201 patients were excluded. The total number
of participants fulfilling the entry criteria on September 30, 2002 was
5292. The Hospital Ethics Committee approved the study.
Clinic Blood Pressure Measurement
A nurse measured blood pressure in the nondominant arm after 5
minutes of quiet sitting in accordance with contemporary recommen-
dations22,23 using either a standard mercury sphygmomanometer or a
calibrated and validated automated sphygmomanometer—the Om-
ron HEM-705CP.24 CBPM was calculated as the mean of 3
measurements.
Ambulatory Blood Pressure Measurement
ABPM measurements were made every half-hour throughout the
24-hour period using SpaceLabs 90202 and 90207 monitors
(SpaceLabs Inc, Wokingham, Berkshire, UK), both of which have
been previously shown to be accurate.25,26 All data were transferred
into a software package (dabl Cardiovascular; Dabl Limited),27
which allows calculation of SBP and DBP for the daytime period
(average of readings between 0900 and 2100 hours), the nighttime
period (average of readings between 0100 and 0600 hours), and the
24-hour period without applying any editing criteria.28,29 ABPM
measurements were time-weighted. Hypertension was defined as a
mean daytime ABPM of 135 mm Hg systolic or 85 mm Hg
diastolic.30
Mortality Outcome
In the absence of a unique identifier to permit ready identification of
subjects on the death register, mortality outcome was ascertained by
searching a national computerized register of deaths for each
individual whose name appeared in the dabl blood pressure database.
This process was completed in a number of stages, which have been
described previously.31 Briefly, the register was first searched for
patients having both similar names and approximate date of birth, so
as to allow for different versions of first and surnames and/or
misspelling in the death certificate, and also to overcome the
omission of the actual date of birth by allowing a 2-year margin of
error. If there was no match using these 2 criteria, the individual was
considered to be alive. Where there was a positive match, the
relevant death certificate was examined, and further confirmation of
death was sought by checking addresses, hospital records, and family
doctors records. This process provided definite evidence that 646
people from the 5292 individuals in the study cohort had died by
September 30, 2002. Because Irish death certificates state the cause
of death but are not coded, the death certificate of each individual
was examined and the cause of death was coded according to the
World Health Organization’s International Classification of Dis-
eases, 9th Revision (ICD-9).32 Cardiac mortality included myocar-
dial infarction (ICD-9, 4100 to 4109), heart failure (4280 to 4289),
sudden death (7980 to 7989), and chronic coronary heart disease
(4140 to 4149). Cardiovascular mortality consisted of cardiac mor-
tality, stroke (4300 to 4389), and other vascular deaths.
Statistical Analysis
The analyses were performed using SAS software, version 9 (SAS
Institute Inc, Cary, NC). We compared means and proportions by the
large sample z-test and the 2 statistic, respectively. We divided the
distributions of the baseline blood pressure into quintiles. From one
overall logistic regression model adjusted for gender and age, we
computed the risk of an adverse outcome in each blood-pressure
quintile relative to the common risk in all patients. We plotted these
5 risk estimates with 95% confidence intervals (CIs) against the
average blood pressure in each quintile.33 This analysis was per-
formed on ambulatory SBP and DBP to test the hypothesis that
ABPM predicts cardiovascular mortality. We then introduced CBPM
and ABPM, or daytime and nighttime ABPM, as continuous vari-
ables in Cox proportional hazards regression. Relative hazard ratios
TABLE 1. Characteristics of Study Population
Parameters
Alive Dead
Cardiovascular Noncardiovascular
n 4646 389 257
Age, years 51.5 (14.2) 67.5 (11.9)* 64.4 (13.7)
Female, % 54.8 43.5* 48.7
Body mass index, kg/m2 27.5 (3.6) 27.7 (3.4) 25.6 (4.1)
Current smoking, % 22.9 30.6* 29.1
Diabetes, % 4.9 7.7* 5.8
Previous cardiovascular complications, % 9.3 23.1* 15.2
Clinic SBP 161.1 (26.8) 173.7 (31.1)* 167.2 (32.2)
Clinic DBP 93.2 (14.6) 92.3 (16.1) 91.7 (17.8)
Daytime SBP 145.4 (18.4) 153.1 (22.8)* 148.1 (20.4)
Daytime DBP 89.1 (12.5) 88.2 (14.7) 87.7 (13.2)
Nighttime SBP 127.2 (18.7) 142.4 (25.3)* 135.6 (24.1)
Nighttime DBP 74.8 (12.8) 78.8 (15.2)* 77.6 (14.7)
24-hour SBP 137.1 (20.3) 146.3 (25.1)* 143.0 (23.6)
24-hour DBP 82.1 (11.2) 84.6 (13.1)* 83.1 (12.1)
DBP indicates diastolic blood pressure; SBP, systolic blood pressure.
All pressures in mm Hg.
Values are means (SD) or n of subjects (%).
Body mass index is the weight in kilograms divided by the square of height in meters.
*Statistical significance (P0.05) of difference between alive group and cardiovascular dead
group.
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and 95% CIs were calculated for each 10-mm Hg and 5-mm Hg
increase in SBP and DBP, respectively. Adjustments were made for
gender, age, body mass index, presence of diabetes mellitus, history
of cardiovascular events, and current smoking status, along with
further adjustment for CBPM.
Results
Baseline Characteristics
The characteristics of the patient populations are shown in
Table 1. Mean follow-up was 7.9 years (interquartile range,
5.6 years to 10.6 years). Ages at baseline ranged from 16.2
years to 92.4 years. There were 646 deaths, of which 389
were cardiovascular. The prevalence of known cardiovascular
risk factors was higher among patients who died of cardio-
vascular causes.
Clinic and Ambulatory Blood Pressures as
Predictors of Mortality Risk
Using a nonparametric approach with adjustment for gender
and age, patients in the highest quintile for nighttime pres-
sures were at higher relative risk compared with the overall
group (Figure 1). Patients in the highest quintile for nighttime
SBP had a relative risk of a cardiovascular death of 1.30 (95%
CI, 1.17 to 1.45; P0.001).
Table 2 shows the relative hazard ratios for 10- and
5-mm Hg increases in SBP and DBP, respectively, before and
after adjustment for CBPM. With adjustments applied for
baseline characteristics, the systolic ABPM predicted all
mortality outcomes over and beyond systolic CBPM
(P0.001). Table 3 provides the fully adjusted Cox regres-
sion models for cardiovascular mortality and shows that the
significance levels were considerably higher for the ambula-
tory than for the conventional blood pressure. ABPM was not
forced into the models for any of the fatal outcome analyses.
The hazard ratios associated with a 10-mm Hg increase in
SBP were 1.12 (95% CI, 1.06 to 1.19; P0.001), 1.21 (95%
CI, 1.13 to 1.28; P0.001), and 1.19 (95% CI, 1.13 to 1.27;
P0.001) for daytime, nighttime, and 24-hour ABPM, re-
spectively. The corresponding adjusted relative hazard ratios
associated with a 5-mm Hg increase in DBP were 1.03 (95%
CI, 0.99 to 1.07; PNS), 1.07 (95% CI, 1.04 to 1.13;
P0.05), and 1.09 (95% CI, 1.02 to 1.11; P0.01). Night-
time ABPM provides additional predictive information over
daytime ABPM, as does ABPM SBP over ABPM DBP, for
total, cardiovascular, stroke, and cardiac mortality (Table 4).
Figure 1. Associations between cardiovascular mortality and
ambulatory blood pressure in 5292 patients. Solid diamonds
represent risks in quintiles of the blood pressure distributions
relative to common risk in all patients with adjustment applied
to gender and age. Vertical lines denote 95% CIs. Numbers rep-
resent the number of cardiovascular deaths in each quintile.
TABLE 2. Relative Hazard Ratios Associated With Clinic and Ambulatory Blood Pressures
Parameters
Unadjusted for Clinic
Blood Pressure
Adjusted for Clinic
Blood Pressure
All-Cause
Mortality Cardiovascular Stroke Cardiac
All-Cause
Mortality Cardiovascular Stroke Cardiac
No. of events 646 389 103 254 646 389 103 254
Clinic SBP 1.02 (0.99–1.05) 1.06 (1.02–1.10)† 1.07 (1.00–1.15)* 1.06 (1.01–1.10)*
Daytime SBP 1.09 (1.04–1.13)† 1.15 (1.10–1.21)‡ 1.18 (1.08–1.30)† 1.12 (1.06–1.19)† 1.07 (1.03–1.12)† 1.12 (1.06–1.18)‡ 1.17 (1.05–1.30)† 1.11 (1.04–1.19)†
Nighttime SBP 1.14 (1.10–1.18)‡ 1.21 (1.16–1.27)‡ 1.30 (1.19–1.40)‡ 1.16 (1.10–1.23)‡ 1.15 (1.11–1.20)‡ 1.21 (1.15–1.27)‡ 1.30 (1.19–1.42)‡ 1.15 (1.04–1.23)†
24-hour SBP 1.11 (1.07–1.16)‡ 1.19 (1.14–1.26)‡ 1.27 (1.15–1.40)‡ 1.17 (1.09–1.24)‡ 1.13 (1.08–1.19)‡ 1.19 (1.13–1.27)‡ 1.28 (1.15–1.43)‡ 1.16 (1.07–1.25)‡
Clinic DBP 1.01 (0.99–1.04) 1.03 (1.00–1.07)* 1.06 (0.99–1.12) 1.02 (0.98–1.06)
Daytime DBP 1.02 (0.99–1.06) 1.04 (1.00–1.08)* 1.09 (1.01–1.17)* 1.03 (0.98–1.07) 1.02 (0.99–1.05) 1.03 (0.99–1.07) 1.07 (0.99–1.16) 1.02 (0.97–1.07)
Nighttime DBP 1.07 (1.04–1.10)† 1.09 (1.05–1.13)† 1.14 (1.07–1.22)† 1.06 (1.01–1.11)* 1.08 (1.04–1.11)‡ 1.09 (1.04–1.13)‡ 1.14 (1.06–1.22)‡ 1.06 (1.01–1.11)*
24-hour DBP 1.06 (1.02–1.09)* 1.07 (1.03–1.12)† 1.13 (1.05–1.22)† 1.05 (1.00–1.10) 1.05 (1.02–1.09)* 1.09 (1.02–1.11)† 1.12 (1.03–1.22)* 1.05 (0.99–1.11)
Relative hazard ratios (95% confidence intervals) for each 10-mm Hg increase in systolic pressure and 5-mm Hg increase in diastolic pressure with adjustments
applied for baseline characteristics including gender, age, body mass index, presence of diabetes mellitus, history of cardiovascular events, and smoking status, along
with further adjustment for clinic blood pressure measurement.
Cardiac fatal endpoint includes heart failure, myocardial infarction, and sudden death.
Significance of the hazard ratios: *P0.05, †P0.01, ‡P0.001.
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Figure 2 demonstrates the absolute 5-year cardiovascular risk,
after adjustment for other covariates, in relation to baseline
ABPM and CBPM.
Discussion
To our knowledge, this single-center study is the largest to
date to demonstrate that ABPM is a stronger predictor of
cardiovascular mortality than CBPM, and that nighttime is
superior to daytime ABPM in predicting cardiovascular
mortality in a Western hypertensive population who were not
using antihypertensive medication at the time of blood
pressure measurement. A possible limitation to our study
might have been the omission of deaths because of patients
leaving the jurisdiction or changing names as a consequence
of marriage. However, given the mean age of the patients,
these occurrences are not likely to have been significant. We
did not have sufficient data on antihypertensive medication
during follow-up to adjust for the potential effect of treatment
on outcome.
The classic study by Perloff et al in 1983 was the first to
demonstrate that ABPM was a better predictor of morbidity
than CBPM in hypertensive patients.5 Since then, a number of
TABLE 3. Relative Hazard Ratios Independently Associated With Daytime and Nighttime
Systolic and Diastolic Ambulatory Blood Pressure
Model All-Cause Mortality Cardiovascular Stroke Cardiac
n of events 646 389 103 254
Model 1 Daytime SBP 0.95 (0.90–1.00) 0.96 (0.90–1.04) 0.95 (0.83–1.08) 1.01 (0.93–1.10)
Nighttime SBP 1.18 (1.12–1.24)‡ 1.23 (1.15–1.31)‡ 1.34 (1.19–1.50)‡ 1.15 (1.06–1.25)†
Model 2 Daytime DBP 0.95 (0.92–0.99)* 0.96 (0.91–1.01) 0.98 (0.89–1.08) 0.97 (0.91–1.04)
Nighttime DBP 1.11 (1.06–1.15)‡ 1.12 (1.06–1.17)† 1.16 (1.06–1.27)† 1.08 (1.01–1.15)*
Model 3 Daytime SBP 1.10 (1.04–1.16)‡ 1.19 (1.11–1.27)‡ 1.20 (1.06–1.36)† 1.18 (1.10–1.28)‡
Daytime DBP 0.97 (0.94–1.02) 0.95 (0.90–1.00)* 0.98 (0.89–1.09) 0.94 (0.89–1.00)
Model 4 Nighttime SBP 1.16 (1.10–1.22)‡ 1.29 (1.21–1.38)‡ 1.37 (1.21–1.55)‡ 1.24 (1.14–1.35)‡
Nighttime DBP 0.98 (0.94–1.03) 0.93 (0.88–0.99)* 0.94 (0.85–1.04) 0.93 (0.87–1.00)*
Model 1daytime SBP, nighttime SBP, gender, age, body mass index, presence of diabetes mellitus, history of
cardiovascular events, and current smoking status.
Model 2daytime DBP, nighttime DBP, gender, age, body mass index, presence of diabetes mellitus, history of
cardiovascular events, and current smoking status.
Model 3daytime SBP, daytime DBP, gender, age, body mass index, presence of diabetes mellitus, history of
cardiovascular events, and current smoking status.
Model 4nighttime SBP, nighttime DBP, gender, age, body mass index, presence of diabetes mellitus, history of
cardiovascular events, and current smoking status.
Relative hazard ratios (95% confidence intervals) for each 10-mm Hg increase in systolic pressure and 5-mm Hg
increase in diastolic pressure. Hazard ratios were also adjusted for baseline characteristics including gender, age,
body mass index, presence of diabetes mellitus, history of cardiovascular events, and current smoking status.
Significance of the hazard ratios: *P0.05, †P0.01, ‡P0.001.
TABLE 4. Description of Fully Adjusted Models With All Relative Hazard Ratios Included for Cardiovascular Mortality
Parameter SBP Daytime SBP Nighttime SBP 24-Hour DBP Daytime DBP Nighttime DBP 24-Hour
ABPM 1.12 (1.06–1.18)‡ 1.21 (1.15–1.27)‡ 1.19 (1.13–1.27)‡ 1.03 (0.99–1.07) 1.09 (1.04–1.13)‡ 1.09 (1.02–1.11)†
Clinic SBP 1.02 (0.98–1.06) 1.01 (0.97–1.04) 1.00 (0.96–1.04)
Clinic DBP 1.02 (0.99–1.06) 1.01 (0.97–1.04) 1.01 (0.98–1.05)
Gender 1.99 (1.62–2.44)‡ 2.01 (1.64–2.47)‡ 1.99 (1.62–2.45)‡ 1.93 (1.57–2.37)‡ 1.83 (1.49–2.25)‡ 1.87 (1.52–2.30)‡
Age 1.10 (1.09–1.11)‡ 1.09 (1.08–1.10)‡ 1.09 (1.08–1.10)‡ 1.10 (1.09–1.11)‡ 1.10 (1.09–1.11)‡ 1.10 (1.09–1.11)‡
Body mass index 0.97 (0.95–1.00) 0.98 (0.95–1.00) 0.97 (0.95–1.00) 0.97 (0.95–1.00) 0.98 (0.95–1.00) 0.98 (0.95–1.00)
Diabetes mellitus 1.33 (0.91–1.94) 1.30 (0.89–1.89) 1.31 (0.90–1.91) 1.37 (0.94–1.99) 1.38 (0.95–2.02) 1.37 (0.94–2.00)
History of cardiovascular
disease
1.67 (1.31–2.13)‡ 1.63 (1.28–2.07)‡ 1.66 (1.31–2.12)‡ 1.60 (1.26–2.04)‡ 1.60 (1.25–2.03)‡ 1.61 (1.26–2.05)‡
Smoking status 1.87 (1.48–2.37)‡ 1.84 (1.46–2.32)‡ 1.81 (1.43–2.29)‡ 1.95 (1.54–2.46)‡ 1.93 (1.53–2.43)‡ 1.92 (1.52–2.42)‡
ABPM indicates ambulatory blood pressure measurement.
All models include ABPM, CBPM, gender, age, body mass index, presence of diabetes mellitus, history of cardiovascular events, and smoking status.
Relative hazard ratios (95 % confidence intervals) for each 10-mm Hg increase in SBP and 5-mm Hg increase in DBP, male gender, 1 year increase in age, 1 kg/m2
increase in body mass index, the presence of diabetes mellitus, a positive history of cardiovascular events, and positive smoking status.
Significance of the hazard ratios: *P0.05, †P0.01, ‡P0.001.
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studies have confirmed that ABPM is a stronger predictor of
outcome than CBPM.5–13 A study in Spanish patients with
refractory hypertension showed that patients with daytime
ABPM in the lowest tertile (DBP 88 mm Hg) had a
significantly lower rate of cardiovascular events over 4-year
follow-up, irrespective of clinic pressures.6 In 808 patients
followed-up for 4.4 years in the placebo-controlled Syst-Eur
trial, cardiovascular risk was 10% between the lowest and
highest CBPMs, whereas the difference was 50% between
the lowest and highest ABPM recordings.7 A prospective
Japanese study in 1542 patients showed that ABPM was a
better predictor of mortality than screening blood pressure,8
and a further analysis has shown that ABPM is also a stronger
predictor of stroke.9 In the Office versus Ambulatory blood
pressure (OvA) study, both DBP and SBP ABPM predicted
cardiovascular death in treated hypertensive patients after
adjustment for CBPM.10 The results of our single-center
study in a large population confirm the superiority of ABPM
over CBPM in predicting cardiovascular mortality.
The dipper/nondipper classification of nocturnal blood pres-
sure was first introduced in 1988 when a retrospective analysis
suggested that nondipping hypertensive patients had a higher
risk of stroke than the majority of patients with a dipping
pattern.14 Since then, there have been many studies evaluating
morbidity and dipping status, and although there has been some
disagreement in the literature, on balance, most large-scale
prospective studies support the concept that a diminished noc-
turnal blood pressure decline is associated with a worse prog-
nosis.17,18 Moreover, 3 longitudinal studies conducted in patients
with hypertension have shown that a diminished nocturnal
decline in blood pressure predicts cardiovascular events.7,19,20
The first prospective study to demonstrate that a diminished
nocturnal decline in blood pressure is a risk factor for cardio-
vascular mortality, independent of the overall blood pressure
load during a 24-hour period, was the Ohasama study in a
Japanese population, which showed that, on average, each 5%
decrease in the decline in nocturnal blood pressure was associ-
ated with20% greater risk of cardiovascular mortality. Impor-
tantly, this association was observed not only in hypertensive
individuals but also in normotensive individuals.21 The results of
our study confirm that the important Japanese finding of a higher
nocturnal blood pressure being a predictor of mortality is also
true for a Western population. In our study, for each 10-mm Hg
increase in mean nighttime SBP, the mortality risk increased by
21%.
The findings of our study have clinical relevance. Despite the
abundance of evidence that ABPM is superior to CBPM, current
guidelines generally recommend ABPM only for selected cir-
cumstances, such as the exclusion of white-coat hypertension.
Our findings support the recommendation that ABPM is indis-
pensable to the management of hypertension and that all patients
with elevated CBPM should have an ABPM.3 Moreover, the
emerging importance of nocturnal blood pressure as an indepen-
dent risk for cardiovascular outcome strengthens the call for
24-hour measurement of blood pressure. Future guidelines will
have to address these issues.
Perspectives
This study has important clinical implications. First, we have
shown in a large cohort of untreated hypertensive patients
that increasing levels of CBPM provide only a modest
increase in cardiovascular risk compared with nighttime or
24-hour ABPM. Second, because patients with elevated
ABPM are at greater risk, irrespective of CBPM, the ready
availability of ABPM in clinical practice would permit
treatment to be targeted at the patients likely to benefit most.
Third, the strong predictive value of nighttime blood pressure
makes it important in clinical practice to direct more attention
to nocturnal blood pressure, and this observation raises an
interesting hypothesis for a prospective randomized clinical
trial to show if treatment based on nighttime pressure will
improve outcome.
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